A Labeled Caution That Doesn't Ask What Kind of Pancreatitis
The label says prior pancreatitis, full stop. His actual history is more specific than that — and whether that specificity should change the decision is the real disagreement.
Anthony B., a 49-year-old man, manages a small fleet of food trucks around the city, work that keeps him tasting other people's cooking most days and has made portion control, in his own words, "basically a full-time second job." He has type 2 diabetes of five years' duration and a BMI of 34, currently controlled only modestly on metformin with an A1c of 8.4%, and both his endocrinologist and primary care physician agree he'd likely benefit substantially from a GLP-1 receptor agonist — strong glycemic effect, real weight-loss benefit, exactly the profile his case calls for. Three years ago, he was hospitalized for acute pancreatitis, subsequently attributed to gallstones on imaging; he underwent a laparoscopic cholecystectomy two months later and has had no recurrent abdominal pain or elevated pancreatic enzymes since.
That history sits directly across the path of the drug the team otherwise agrees would help him most. GLP-1 receptor agonist labeling names prior pancreatitis as a reason for caution, a warning that predates and doesn't distinguish between causes — biliary, alcohol-related, idiopathic, or otherwise. The two large cardiovascular outcome trials most often cited on this question, LEADER and SUSTAIN-6, didn't find a statistically significant increase in pancreatitis even among enrolled patients with real risk factors, but neither trial was designed or powered specifically to answer whether a patient with his exact history — one clear biliary episode, cause since removed — carries meaningfully different risk than the broader "any prior pancreatitis" category the label doesn't subdivide.
A label that doesn't subdivide, and a history that arguably should
I'd avoid this class for him. The label is explicit about prior pancreatitis as a reason for caution, and while LEADER and SUSTAIN-6 are reassuring in aggregate, neither was built to rule out a rare recurrence in an individual patient with his specific history. That warning exists for a reason, and I'm not comfortable waiving it on an interpretive argument about his particular cause.
I'd push back on treating his history as generic "prior pancreatitis." His episode was clearly biliary — gallstones on imaging, resolved by cholecystectomy two months later, no recurrence in three years since. That's mechanistically a different risk category than idiopathic or recurrent disease, and the label's blanket language doesn't make that distinction because it can't, not because the distinction isn't real.
And I'd read LEADER and SUSTAIN-6 as more than just "not disproven" — they enrolled real patients with real risk factors and still found no statistically significant signal. That's meaningful reassurance, even granting it's not the same as a trial designed specifically for his exact history.
I don't think this needs to resolve as an unconditional yes or a flat no. Check a baseline lipase today, start the GLP-1 receptor agonist, and give him explicit, concrete instructions on what abdominal pain would mean he needs to call immediately rather than wait it out.
That's not splitting the difference for its own sake — it's matching the actual state of the evidence, which is reassuring but not airtight, with a plan that lets us stop quickly if something real shows up rather than either accepting his risk silently or denying him likely his most effective option on a residual uncertainty neither trial fully resolves.
Semaglutide started after a baseline lipase, with explicit written instructions on symptoms warranting immediate contact. Anthony was told directly why his history was discussed at length rather than simply cleared or denied, and said he appreciated understanding the actual reasoning rather than just being handed a decision.
Not agreed: whether the primary care physician's caution should translate into a formal chart flag for any future prescriber considering this class for him, independent of today's decision. The endocrinologist saw this as unnecessary given the specific reasoning already documented; the primary care physician wanted the flag regardless, arguing the next prescriber may not have this conversation's full context available. Left unresolved.